IPD Analytics

IPD Analytics — A normalized, multi-domain market-access and drug-policy panel sold as the Access Hub subscription, assembled by an in-house clinical research team rather than scraped. Components: (1) Formulary coverage across national and regional insurers with per-drug status and restriction detail, normalized across plans and sliceable by drug, disease class and manufacturer portfolio. (2) Clinical criteria benchmarking collected from six major national plans, capturing every management step a plan applies to a specific therapy (step-therapy sequences, prior-auth criteria, quantity limits)…

IPD Analytics offers (Alternative, Reference, Price, Fundamental) — Multi-module panel: formulary status and restriction records for the commercial drug universe across a set of leading national and regional plans; clinical criteria with full step-level detail for six major national plans; limited-distribution drug networks with membership rosters; therapy cost series at drug, disease-class and manufacturer-portfolio grain with stated historical depth; a 750+ clinical guideline library; biomarker test records carrying price, payer coverage and patient-assistance status; nonessential drug lists by state; and state Medicaid PDL meeting records with agendas, dates, outcomes and public comments, each with indexed drugs and indications. Combined, this is a multi-domain panel in the low millions of drug x plan x policy observations, though no aggregate record count is published..

Payer formulary and utilization-management design with competitor benchmarking (the step-level criteria from six national plans is the direct comparison set); manufacturer market-access and contracting strategy, including launch sequencing by plan and state; specialty-pharmacy and limited-distribution network planning, since authorized-network membership determines which pharmacy captures a specialty script and therefore referral and revenue forecasts; prior-authorization automation and clinical-criteria grounding for provider revenue cycle; biomarker and companion-diagnostic market sizing, where test pricing plus payer coverage is the binding constraint on precision-medicine volume and is thinly covered anywhere; Medicaid preferred-drug-list pipeline forecasting from meeting agendas and outcomes ahead of publication, which is genuine timing alpha; therapy cost trend and inflation modeling by class and portfolio for actuarial and employer benefit design; and as training data, the drug-to-guideline-citation and policy-text-to-restriction-type pairs are strong supervised sets for regulatory-document extraction models.